Welcome to our dedicated page for Kiniksa Pharmaceuticals International, plc news (Ticker: KNSA), a resource for investors and traders seeking the latest updates and insights on Kiniksa Pharmaceuticals International, plc stock.
Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) generates frequent news through its work as a biopharmaceutical company focused on cardiovascular indications and diseases with unmet need. Company press releases and Form 8‑K filings highlight developments around its IL‑1 pathway franchise, including the commercial performance of ARCALYST (rilonacept) and the clinical progress of investigational monoclonal antibodies KPL‑387 and KPL‑1161.
News items commonly cover quarterly and annual financial results, where Kiniksa reports ARCALYST net product revenue, trends in prescriber adoption, and changes in guidance for expected ARCALYST net product revenue. These updates often include commentary on the uptake of IL‑1α and IL‑1β inhibition in recurrent pericarditis, the proportion of multiple‑recurrence patients on ARCALYST therapy, and the average duration of treatment.
Investors following KNSA news also see regular clinical and regulatory milestones. Kiniksa has announced the initiation and design of a Phase 2/3 clinical trial of KPL‑387 in recurrent pericarditis, Phase 1 data supporting a monthly dosing profile, and the U.S. FDA’s Orphan Drug Designation for KPL‑387 for the treatment of pericarditis. Additional updates describe preclinical or IND‑enabling activities for KPL‑1161, which has a target profile of quarterly subcutaneous dosing.
Corporate and investor‑relations announcements form another key part of the KNSA news flow. The company frequently issues notices about upcoming and completed presentations at healthcare and investor conferences, such as the J.P. Morgan Healthcare Conference, Jefferies Global Healthcare Conference, and other biopharma‑focused events. These communications typically reference webcasts and replays available through Kiniksa’s investor channels.
By monitoring this news stream, readers can track how Kiniksa manages ARCALYST commercialization, advances its IL‑1R1‑targeted pipeline, and updates its financial outlook. The KNSA news page on Stock Titan aggregates these releases so investors and observers can review earnings announcements, trial updates, regulatory designations, and conference participation in one place.
Kiniksa Pharmaceuticals (KNSA) reported net product revenue of $39.9 million for Q4 2022 and $122.5 million for full-year 2022. The company's cash reserves of $190.4 million are projected to support operations through 2025. Kiniksa has enrolled 2 of 3 cohorts in the Phase 2 trial of KPL-404 for rheumatoid arthritis, with results expected in 1H 2024. The company aims to grow its cardiovascular franchise through ARCALYST sales and collaborative agreements for mavrilimumab, indicating a focus on strategic portfolio optimization.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will present at the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 1:30 p.m. PT (4:30 p.m. ET). The presentation will be accessible via a live webcast on the company’s website, with a replay available within approximately 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for diseases with significant unmet medical needs, featuring assets like ARCALYST®, KPL-404, and mavrilimumab, which aim to address underserved conditions by modulating immunological pathways.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced participation in the Bank of America Securities 2022 Biotech SMID Cap Conference, set for December 7, 2022, at 10:15 a.m. Eastern Time. This event will feature a fireside chat with management. Investors can access a live webcast via the company's website, with a replay available approximately 48 hours post-event. Kiniksa is dedicated to developing therapeutic medicines for serious diseases and boasts a portfolio that includes ARCALYST®, KPL-404, and mavrilimumab.
Kiniksa Pharmaceuticals, Ltd. (KNSA) will participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Conference on November 30, 2022, at 10:05 a.m. ET. A live webcast will be available on Kiniksa's website, with a replay accessible within 48 hours after the event. Kiniksa focuses on developing therapeutic medicines for debilitating diseases with significant unmet medical needs, featuring assets like ARCALYST®, KPL-404, and mavrilimumab, which target underserved conditions and modulate immunological pathways.
Kiniksa Pharmaceuticals reported Q3 2022 net revenue of $99.1 million, significantly up from $12.1 million in Q3 2021. ARCALYST net revenue was $33.4 million, with promising long-term data showing a 98.2% risk reduction in recurrent pericarditis events beyond 18 months (Hazard Ratio = 0.018, p<0.0001). The company anticipates ARCALYST full-year revenues of $115 million to $130 million and has cash reserves of $200.7 million to fund operations into at least 2025.
Kiniksa Pharmaceuticals, Ltd. (KNSA) announced a conference call and live webcast on November 1, 2022, at 8:30 a.m. ET to discuss its third quarter 2022 financial results and corporate activities. Interested participants can access the call via Kiniksa's website or register for telephone participation. A replay will be available approximately 48 hours after the event. Kiniksa focuses on developing therapeutic medicines addressing significant unmet medical needs, with assets including ARCALYST, KPL-404, and mavrilimumab.
Kiniksa Pharmaceuticals (Nasdaq: KNSA) has finalized a global license agreement with Roche and Genentech for the development of vixarelimab, a monoclonal antibody targeting oncostatin M receptor beta (OSMRβ). Kiniksa will receive $100 million upfront: $80 million within 30 days and $20 million post-delivery of drug supplies. Additionally, Kiniksa could earn up to $600 million in milestones and royalties based on sales. The company expects this funding to sustain its operations through at least 2025.
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced participation in the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 2:55 p.m. ET. The management will engage in a fireside chat, showcasing the company’s commitment to addressing unmet medical needs through innovative biopharmaceuticals.
A live webcast will be available on Kiniksa’s website, with a replay accessible 48 hours after the event, ensuring broad outreach to investors and stakeholders.
Kiniksa Pharmaceuticals reported Q2 2022 net revenue of $27 million from ARCALYST, marking a significant increase from $7.7 million in Q2 2021. The company expects full-year ARCALYST revenue between $115 million and $130 million. An upfront payment of $100 million is anticipated from a global license agreement with Genentech for vixarelimab, which will support operations into at least 2025. Kiniksa's net loss narrowed to $20 million from $41.6 million year-over-year. The company plans to enhance its sales team in Q4 2022.
Kiniksa Pharmaceuticals (KNSA) has entered a global licensing agreement with Roche and Genentech for the development and commercialization of vixarelimab, a monoclonal antibody targeting OSMRβ. Kiniksa will receive $100 million upfront and is eligible for up to $600 million in future milestones, along with royalties on net sales. The deal focuses on fibrotic indications where OSMRβ plays a critical role. Kiniksa plans to use the non-dilutive capital to expand its ARCALYST cardiovascular franchise. This agreement highlights Kiniksa's commitment to addressing significant unmet medical needs.